Acumen Pharmaceuticals, Inc. (ABOS) stock
ABOSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.21−0.00 (-1.83%)
Close on Nov 13, 2026Market cap $15.48MP/E –Yield –
Acumen Pharmaceuticals total assets
Total assets on the balance sheet at the end of each period.
Acumen Pharmaceuticals's total assets was $85.57M at Sep 30, 2026. For fiscal 2025 it was $122.83M, down 48.6% from the year before. The highest annual figure on record is $310.13M in fiscal 2023.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $122.83M | -48.6% |
| FY2024 | Dec 31, 2024 | $238.99M | -22.9% |
| FY2023 | Dec 31, 2023 | $310.13M | +57.8% |
| FY2022 | Dec 31, 2022 | $196.59M | -14.6% |
| FY2021 | Dec 31, 2021 | $230.33M | +418.4% |
| FY2020 | Dec 31, 2020 | $44.43M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $85.57M | -39.8% |
| Q2 FY2026 | Jun 30, 2026 | $116.01M | -32.5% |
| Q1 FY2026 | Mar 31, 2026 | $133.63M | -34.6% |
| Q4 FY2025 | Dec 31, 2025 | $122.83M | -48.6% |
| Q3 FY2025 | Sep 30, 2025 | $142.22M | -46.7% |
| Q2 FY2025 | Jun 30, 2025 | $171.90M | -40.5% |
| Q1 FY2025 | Mar 31, 2025 | $204.48M | -32.1% |
| Q4 FY2024 | Dec 31, 2024 | $238.99M | -22.9% |
| Q3 FY2024 | Sep 30, 2024 | $266.98M | -6.8% |
| Q2 FY2024 | Jun 30, 2024 | $288.91M | +62.9% |
| Q1 FY2024 | Mar 31, 2024 | $300.97M | +60.2% |
| Q4 FY2023 | Dec 31, 2023 | $310.13M | +57.8% |
| Q3 FY2023 | Sep 30, 2023 | $286.37M | +40.9% |
| Q2 FY2023 | Jun 30, 2023 | $177.41M | -16.2% |
| Q1 FY2023 | Mar 31, 2023 | $187.86M | -14.6% |
| Q4 FY2022 | Dec 31, 2022 | $196.59M | -14.6% |
| Q3 FY2022 | Sep 30, 2022 | $203.26M | -13.4% |
| Q2 FY2022 | Jun 30, 2022 | $211.68M | +190.2% |
| Q1 FY2022 | Mar 31, 2022 | $220.09M | +395.4% |
| Q4 FY2021 | Dec 31, 2021 | $230.33M | – |
| Q3 FY2021 | Sep 30, 2021 | $234.85M | – |
| Q2 FY2021 | Jun 30, 2021 | $72.94M | – |
| Q4 FY2020 | Dec 31, 2020 | $44.43M | – |
See a number that looks wrong?